We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Partners to Seek Novel Drugs to Treat Fibrotic Diseases

By LabMedica International staff writers
Posted on 26 Jul 2015
Print article
A global biopharmaceutical company and an American university hospital-based research institute have agreed to collaborate on the diagnosis and cure of fibrotic diseases.

Fibrotic diseases such as scleroderma, renal fibrosis, and idiopathic pulmonary fibrosis are characterized by the gradual formation of excess fibrous connective tissue in an organ or tissue.

The Medical University of South Carolina (Charleston, USA) and the global pharmaceutical company Bristol-Myers Squibb (New York, NY, USA) announced that they have entered into a translational research collaboration focused on identifying novel medicines to halt or slow the progression of fibrotic disease. The agreement also provides for studies designed to improve the mechanistic understanding of fibrosis and to explore patient segmentation based on disease characteristics and/or biomarker approaches and predictors of disease progression.

“Bristol-Myers Squibb’s collaboration with the Medical University of South Carolina further strengthens and advances our discovery research efforts in fibrotic diseases, a strategic area of focus for the company,” said Dr. Carl Decicco, head of discovery research and development at Bristol-Myers Squibb. “The Medical University of South Carolina brings substantial expertise in translational research and drug discovery related to fibrotic diseases including access to patient derived disease tissue samples that will help us accelerate the application of scientific knowledge to potential new treatment approaches for patients.”

“This is an exciting opportunity with the potential to make a significant impact in fibrotic diseases and in patients’ lives with these debilitating diseases,” said Dr. Karen Lackey, associate professor of pharmacy and executive director for therapeutic discovery development at the Medical University of South Carolina. “Our goal with translational research is to shorten the timeline in getting patients the medications and treatments they need. We have unparalleled expertise in fibrosis research at the Medical University of South Carolina, and this collaboration with a leader like Bristol-Myers Squibb in discovery and development of medications is going to take that foundational work to the next level.”

Related Links:

The Medical University of South Carolina
Bristol-Myers Squibb


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.